Medical/Pharmaceuticals
Qilian International Holding Group Limited Announces Inclusion of Gan Di Xin® and Qilian Shan® Oxytetracycline into List for Development of Leading Enterprises with Large Varieties and Brands of Pharmaceuticals of Gansu Province
JIUQUAN, China, Nov. 23, 2021 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), aChina-based pharmaceutical and chemical products manufacturer, today announced that Gan Di Xin® and Qilian Shan® Oxytetracycline, products of the Company's subsidiary, Gansu Qi...
2021-11-23 20:00
2544
Bionomics Files Registration Statement for Proposed Initial Public Offering in the United States
ADELAIDE, Australia, Nov. 23, 2021 /PRNewswire/ -- Bionomics Limited (ASX:BNO, OTCQB:BNOEF) (Bionomics or Company), a clinical-stage biopharmaceutical company, today announced the public filing of a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the "SEC") in...
2021-11-23 19:37
4165
Simcere and Shanghai Institute of Materia Medica Enter a Collaboration to Jointly Develop Next-Gen COVID-19 Oral Antiviral Treatments
NANJING, China, Nov. 22, 2021 /PRNewswire/ -- On November 17, 2021, Simcere Pharmaceutical Group Limited (2096.HK) announced that the company has reached collaboration agreement with the Shanghai Institute ofMateria Medica (SIMM), Chinese Academy of Sciences (CAS), to develop novel antiviral drug...
2021-11-23 11:22
2907
Trajan Group acquires Axel Semrau GmbH
MELBOURNE, Australia, Nov. 22, 2021 /PRNewswire/ -- Global analytical science and device company Trajan Group Holdings Limited (ASX: TRJ) (Trajan or the Company) has completed the acquisition of Axel Semrau GmbH & Co. KG and Semrau Immobilien GmbH & Co. KG, the private business and properties of ...
2021-11-22 23:30
2705
Arctic Vision Announces First Patient Dosed in Phase III Study of ARVN001 for Treatment of Macular Edema Associated with Uveitis (UME)
* First-in-class SCS Microinjection therapy * First clinical registration study and potentially the first approved drug in China targeting macular edema associated with uveitis * U.S. FDA approved for treatment of macular edema associated with uveitis SHANGHAI, Nov. 22, 2021 /PRNewswire/ -- A...
2021-11-22 23:17
2014
Ascentage Pharma's Olverembatinib Granted Orphan Designation by the European Commission for the Treatment of Chronic Myeloid Leukemia
SUZHOU, China, and ROCKVILLE, MD., Nov. 22, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the European Commission (EC) has granted the...
2021-11-22 21:24
2341
Bispecific antibody drug against COVID-19 jointly developed by Shanghai ZJ Bio-Tech and Sanyou Biopharmaceuticals appearing at China International Import Expo (CIIE)
SHANGHAI, Nov. 22, 2021 /PRNewswire/ -- At the opening ceremony of the 4th China International Import Expo (CIIE) held inShanghai on November 6, 2021, SYZJ001, a bispecific antibody drug against COVID-19 jointly developed by Shanghai ZJ Bio-Tech Co., Ltd. and Sanyou Biopharmaceuticals (Shanghai) ...
2021-11-22 21:00
1843
TenNor Reports Positive Results of TNP-2092 Capsule for the Treatment of Liver Cirrhosis Hyperammonemia
SUZHOU, China, Nov. 22, 2021 /PRNewswire/ -- TenNor Therapeutics reports positive top-line results for TNP-2092 Capsule from a phase II clinical trial for the treatment of hyperammonemia/hepatic encephalopathy in patients with liver cirrhosis. TNP-2092 Capsule is an investigational new drug produ...
2021-11-22 21:00
1641
CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China
SUZHOU, China, Nov. 21, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, and Jiangsu Hengrui Pharmaceuticals ("Hengru...
2021-11-21 17:02
3953
Nestle Health Science Partners with Healint to Initiate a Fully Virtual Study on Ketogenic Treatment for Migraines
SINGAPORE, Nov. 20, 2021 /PRNewswire/ -- Nestlé Health Science (NHSc) has initiated a study looking into the effectiveness of a ketogenic nutritional supplement in reducing migraine attacks. The fully virtual study, taking place inQuebec, Canada, is investigating the effectiveness of a ketogenic ...
2021-11-21 08:49
3010
Successful 2020 Tang Prize Award Ceremony Highlights Laureates' Achievements and Influence
TAIPEI, Nov. 20, 2021 /PRNewswire/ -- The 2020 Tang Prize Award Ceremony took place virtually at 2p.m. (GMT+8) onNovember 20. Eight 2020 recipients of the prize from seven countries, including the U.S., the U.K.,Japan, Singapore, Bangladesh, Colombia, and Lebanon, attended this heartwarming event...
2021-11-20 15:00
3455
Gracell Biotechnologies Granted FDA Orphan Drug Designation for FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy Candidate GC012F for the Treatment of Multiple Myeloma
SUZHOU and SHANGHAI, China, and PALO ALTO, Calif., Nov. 19, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today ...
2021-11-19 19:00
2896
111, Inc. Announces Third Quarter 2021 Unaudited Financial Results
SHANGHAI, Nov. 19, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced its unaudited financial results for the third quart...
2021-11-19 13:31
3623
ASRA 2021 | Cali Biosciences Presents Phase IIa Clinical Data on CPL-01, a Long-Acting Ropivacaine
SAN DIEGO, Nov. 19, 2021 /PRNewswire/ -- Cali Biosciences, a global biopharmaceutical company focused on the research and development of innovative drugs, presented Phase IIa clinical data today on its perioperative long-acting ropivacaine, CPL- 01, at the 20th Annual American Society of Regional...
2021-11-19 13:14
1697
Development of "VR hands on training" with hand tracking in live-action medical VR!
TOKYO, Nov. 18, 2021 /PRNewswire/ -- Jolly Good Inc. (Chuo-ku, Tokyo, CEO: Kensuke Joji; "Jolly Good") has developed the "VR hands on training" function as a new feature of the "OPECloud VR hands on training system". This is a VR clinical training platform developed and provided by Jolly Good, wh...
2021-11-18 21:00
2075
Clinical Data Shows the Efficacy of In-Phase and Quadrature Demodulation in Electronic Fetal Heart Rate Monitoring During Labor
SHENZHEN, China, Nov. 18, 2021 /PRNewswire/ -- EDAN Instruments
2021-11-18 15:08
2587
China sees huge bounce in pharma rankings ahead of hybrid CPhI & P-MEC China
SHANGHAI, Nov. 18, 2021 /PRNewswire/ -- China's pharma industry has seen a record improvement in its overall score, growth potential and biologics according to new data. TheChina specific findings of the CPhI Annual Report rankings[1] are released ahead of CPhI & P-MEC China - which will take pla...
2021-11-18 15:00
1517
Inmagene files two international patent applications
SHANGHAI and SAN DIEGO and HANGZHOU, China, Nov. 17, 2021 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene" or the "Company") announced that it has filed two international patent applications for its drug candidates, IMG-007 (OX40 antagonist) and IMG-008 (IL-36R antagonist). One application...
2021-11-17 18:30
1974
Terumo Blood and Cell Technologies and Immunicom Establish Agreement to Launch Breakthrough Cancer Immunotherapy Treatment in Europe
* The therapy aims to re-energize a patient's immune system to fight cancer
tumors
* Initial commercialization will target leading oncology centers in Germany,
France, Italy, and Spain LAKEWOOD, Colo. and SAN DIEGO, Nov. 16, 2021
/PRNewswire/ --Terumo Blood and Cell Technologies
2021-11-17 00:00
2161
FibroBiologics Secures $100 Million Capital Commitment from GEM as Company Seeks to Go Public
The Company plans to go public via SPAC, reverse merger, or a direct listing HOUSTON, Nov. 16, 2021 /PRNewswire/ -- FibroBiologics, a clinical stage company developing fibroblast-based therapeutic cures for chronic diseases, announced today that it has signed an agreement with GEM Global Y...
2021-11-16 23:07
1636
Week's Top Stories
Most Reposted
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
The Philippines Sets a New Standard in Muslim-Friendly Tourism
[Picked up by 286 media titles]
2026-05-26 10:30
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 281 media titles]
2026-05-20 09:15ISDN's IDI Dynamics debuts high-speed laser marker for semiconductor assembly and test (OSAT)
[Picked up by 280 media titles]
2026-05-26 08:40
Consistently recognised: Infobip named a Leader in Gartner® Magic Quadrant™ for CPaaS again
[Picked up by 279 media titles]
2026-05-21 16:31
Most Read
NYSE Content Update: Lincoln International Pops by 13% in First Day of Trade
2026-05-21 21:04
8351
Scienjoy Holding Corporation Reports Unaudited First Quarter 2026 Financial Results
2026-05-21 20:30
8106
